STOCK TITAN

Ascendis Pharma A/S American Depositary Shares - ASND STOCK NEWS

Welcome to our dedicated page for Ascendis Pharma A/S American Depositary Shares news (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma A/S American Depositary Shares stock.

Ascendis Pharma A/S (NASDAQ: ASND) is a pioneering biotechnology company located at 12 Tuborg Blvd., Hellerup, Capital Region of Denmark, Denmark. Specializing in the development of prodrug therapies, Ascendis Pharma is leveraging its proprietary TransCon technology to create therapies with improved efficacy and safety profiles that address significant unmet medical needs. The company’s diverse product pipeline includes TransCon growth hormone, TransCon peptides, TransCon PTH, and TransCon CNP, among others.

Ascendis Pharma operates across North America, China, and Europe, with the majority of its revenue derived from North American markets. The firm’s flagship product, SKYTROFA, has become the leading growth hormone product by value in the U.S. Ascendis is also rolling out YORVIPATH in Europe, starting with Germany and Austria. In addition, the company is advancing its clinical program for TransCon CNP.

In 2023, Ascendis undertook a significant restructuring to streamline its operations, processes, and expense allocations. President and CEO Jan Mikkelsen maintains that Ascendis is on track to achieve its ambitious Vision 3x3 and Vision 2030 goals, which include achieving blockbuster status for each of its three independent Endocrinology Rare Disease products and expanding its engine for future innovation.

Financially, Ascendis Pharma reported substantial revenue growth in 2023, with total revenue reaching €266.7 million compared to €51.2 million in 2022. This growth was primarily driven by higher SKYTROFA revenue and an upfront payment from Teijin. Research and development (R&D) expenses also increased to €413.5 million in 2023, reflecting ongoing development activities in their TransCon programs. Despite a net loss for the year, the company's financial health remains robust, with cash, cash equivalents, and marketable securities totaling €399.4 million as of December 31, 2023.

Looking ahead, Ascendis Pharma has several key milestones slated for 2024, including the expected commercial launch of TransCon PTH in the U.S. and advancing its oncology and ophthalmology programs. The company also plans to achieve operating cash flow breakeven on a quarterly basis by the end of the year.

Ascendis continues to focus on leveraging its TransCon technology to develop therapies that can make a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis Pharma is committed to becoming a leading, fully integrated biopharma company.

Rhea-AI Summary
Ascendis Pharma to participate in three upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
conferences
-
Rhea-AI Summary
Ascendant Resources announces results of annual and special meeting of shareholders
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Ascendis Pharma A/S (Nasdaq: ASND) to report Q2 2023 financial results and business update on September 5, 2023. Conference call and webcast to discuss financial results and operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none

FAQ

What is the current stock price of Ascendis Pharma A/S American Depositary Shares (ASND)?

The current stock price of Ascendis Pharma A/S American Depositary Shares (ASND) is $129.81 as of November 22, 2024.

What is the market cap of Ascendis Pharma A/S American Depositary Shares (ASND)?

The market cap of Ascendis Pharma A/S American Depositary Shares (ASND) is approximately 7.6B.

What is Ascendis Pharma A/S's primary focus?

Ascendis Pharma A/S focuses on developing prodrug therapies using its proprietary TransCon technology to meet significant unmet medical needs.

Where is Ascendis Pharma A/S located?

Ascendis Pharma A/S is located at 12 Tuborg Blvd., Hellerup, Capital Region of Denmark, Denmark.

What are some of Ascendis Pharma's key products?

Key products include SKYTROFA, YORVIPATH, TransCon growth hormone, TransCon peptides, TransCon PTH, and TransCon CNP.

In which regions does Ascendis Pharma operate?

Ascendis Pharma operates in North America, China, and Europe.

What were Ascendis Pharma's total revenues for 2023?

In 2023, Ascendis Pharma reported total revenues of €266.7 million.

What major milestones does Ascendis Pharma plan to achieve in 2024?

In 2024, Ascendis Pharma plans to launch TransCon PTH in the U.S. and continue advancing its oncology and ophthalmology programs.

What is the Vision 2030 goal for Ascendis Pharma?

The Vision 2030 goal includes achieving blockbuster status for each of its three independent Endocrinology Rare Disease products and expanding its engine for future innovation.

How much cash and marketable securities did Ascendis Pharma have at the end of 2023?

As of December 31, 2023, Ascendis Pharma had cash, cash equivalents, and marketable securities totaling €399.4 million.

What technology platform does Ascendis Pharma use for developing its therapies?

Ascendis Pharma uses its innovative TransCon technology platform to develop its therapies.

What are Ascendis Pharma's core values?

Ascendis Pharma's core values are Patients, Science, and Passion.

Ascendis Pharma A/S American Depositary Shares

Nasdaq:ASND

ASND Rankings

ASND Stock Data

7.63B
60.07M
0.73%
107.12%
5.7%
Biotechnology
Healthcare
Link
United States of America
Hellerup